Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

Virtus LifeSci Biotech Clinical Trials ETF BBC is probably on the radar for investors seeking momentum. The fund just hit a ...

Fintel reports that on October 31, 2025, HC Wainwright & Co. maintained coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

The company aims to raise Rs 27.52 crore via public issue of 21.5 lakh shares at the upper price band. This is purely a fresh ...

Wellgistics Health (WGRX) soared 155% after a Datavault AI tie-up, stirring buzz around AI and healthcare ETFs.

For Indian pharmaceutical companies that already supply nearly half of all generic medicines sold in the US, the decision ...

Bluehill Capital, SOSV, and other global investors participated in the round. The Hyderabad- and US-based biotech startup ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

It's time for the Halloween Effect! Check out ETFs like IYG, IYF, KBWB, XLV, XBI, SMH, FTXL, SPSM & VIOO that could shine from November -- April!